Issues
-
Cover Image
Cover Image
ΚΒ3-1 cells selected for resistance to paclitaxel in the presence of a P-glycoprotein reversal agent display a mutation in β.-tubulin at Asp26Glu. Computational modeling associated with the single point mutation in tubulin is consistent with differing resistance observed between paclitaxel and other taxanes as depicted by detailed interaction models of paclitaxel and docetaxel in wild type β.-tubulin (top) and paclitaxel in Asp26Glu mutant β.-tubulin (bottom). In this issue, Hari and coworkers consider the resistance as a function of both impaired drug binding and microtubule instability.
- PDF Icon PDF LinkTable of Contents
Commentary
Review
ARTICLE
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.